Consensus on potential biomarkers developed for use in clinical tests for schizophrenia

Author:

Lin Ping,Sun Junyu,Lou Xiaoyan,Li Dan,Shi Yun,Li Zhenhua,Ma Peijun,Li Ping,Chen Shuzi,Jin Weifeng,Liu Shuai,Chen Qing,Gao Qiong,Zhu Lili,Xu Jie,Zhu Mengyuan,Wang Mengxia,Liang Kangyi,Zhao Ling,Xu Huabin,Dong Ke,Li Qingtian,Cheng Xunjia,Chen JinghongORCID,Guo Xiaokui

Abstract

BackgroundSchizophrenia is a serious mental illness affecting approximately 20 million individuals globally. Both genetic and environmental factors contribute to the illness. If left undiagnosed and untreated, schizophrenia results in impaired social function, repeated hospital admissions, reduced quality of life and decreased life expectancy. Clinical diagnosis largely relies on subjective evidence, including self-reported experiences, and reported behavioural abnormalities followed by psychiatric evaluation. In addition, psychoses may occur along with other conditions, and the symptoms are often episodic and transient, posing a significant challenge to the precision of diagnosis. Therefore, objective, specific tests using biomarkers are urgently needed for differential diagnosis of schizophrenia in clinical practice.AimsWe aimed to provide evidence-based and consensus-based recommendations, with a summary of laboratory measurements that could potentially be used as biomarkers for schizophrenia, and to discuss directions for future research.MethodsWe searched publications within the last 10 years with the following keywords: ‘schizophrenia’, ‘gene’, ‘inflammation’, ‘neurotransmitter’, ‘protein marker’, ‘gut microbiota’, ‘pharmacogenomics’ and ‘biomarker’. A draft of the consensus was discussed and agreed on by all authors at a round table session.ResultsWe summarised the characteristics of candidate diagnostic markers for schizophrenia, including genetic, inflammatory, neurotransmitter, peripheral protein, pharmacogenomic and gut microbiota markers. We also proposed a novel laboratory process for diagnosing schizophrenia in clinical practice based on the evidence summarised in this paper.ConclusionsFurther efforts are needed to identify schizophrenia-specific genetic and epigenetic markers for precise diagnosis, differential diagnosis and ethnicity-specific markers for the Chinese population. The development of novel laboratory techniques is making it possible to use these biomarkers clinically to diagnose disease.

Funder

Shanghai Natural Science fund Project under Grant

The National Key Development Plan for Precision Medicine Research

The hospital-level project of Shanghai Mental Health Center under Grant

Special Fund for Clinical Research of Wu Jieping Medical Foundation

The Hospital level project of Shanghai Mental Health Center

Chinese medicine research project of Shanghai Health and Family Planning Commission

The Characteristic discipline construction project of Shanghai Mental Health Center

China Public Health Alliance

Publisher

BMJ

Subject

Psychiatry and Mental health,Neurology (clinical),Neurology

Reference136 articles.

1. Schizophrenia

2. Balancing therapeutic safety and efficacy to improve clinical and economic outcomes in schizophrenia: a clinical overview;Javitt;Am J Manag Care,2014

3. Variations in the Incidence of Schizophrenia: Data Versus Dogma

4. Seasonality of births in schizophrenia and bipolar disorder: a review of the literature

5. Elevated Maternal Interleukin-8 Levels and Risk of Schizophrenia in Adult Offspring

Cited by 12 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3